There has been strong revenues and profit across Blade's many business lines this quarter. Flyers are loyal and the organ transplant business is delivering accelerated growth.

Blade has agreed to purchase 100% of Trinity's capital stock for an upfront fee of approximately $23 million, with the potential for more based on Trinity's performance over the next three years.